Executive interview – Silence Therapeutics

Executive interview – Silence Therapeutics

In this interview with David Horn Solomon, CEO of Silence Therapeutics, he discusses today’s announcement of a licensing and collaboration agreement with Mallinckrodt Pharmaceuticals to develop and commercialise RNAi drugs.


You may also be interested in these:

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free